Johnson & Johnson demonstrated resilience in Q1 2020 with strong growth in Consumer Health and Pharmaceuticals segments, bolstered by increased demand due to the COVID-19 pandemic. Although the Medical Devices segment experienced declines, the company's proactive measures and optimistic guidance regarding vaccine development and business continuity provide confidence in its ability to navigate short-term challenges. The steady dividend increase further reinforces investor confidence.

[1]